Gene expression on liver toxicity induced by administration of haloperidol in rats with severe fatty liver

Legal Medicine

Volumn 10, Issue 4, 2008, Pages 177-184

  Hanagama, Masakazu ^a   Inoue, Hiromasa ^a   Kamiya, Munechika ^a   Shinone, Kotaro ^a   Nata, Masayuki ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Cytochrome P450; Fatty liver; Haloperidol; Schizophrenia; Sudden death

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C11; CYTOCHROME P450 3A2; HALOPERIDOL; MESSENGER RNA; NEUROLEPTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG METABOLISM; FATTY LIVER; GENE EXPRESSION; HISTOLOGY; LIVER TOXICITY; MALE; MOLECULAR BIOLOGY; NONHUMAN; RAT;

EID: 43049180032     PISSN: 13446223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.legalmed.2007.12.006     Document Type: Article

References (52)

1. G.W. Hugenholtz E.R. Heerdink J.J. Stolker W.E. Meijer A.C. Egberts W.A. Nolen Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses J Clin Psychiatry 67 2006 897 903
2. E. Usuki C.J. Van der Schyf N. Castagnoli Jr. Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP Drug Metab Rev 30 1998 809 826
3. A. Rosh B.A. Sampson C.S. Hirsch Schizophrenia as a cause of death J Forensic Sci 48 2003 164 167
4. S. Hennessy W.B. Bilker J.S. Knauss D.J. Margolis S.E. Kimmel R.F. Reynolds Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data BMJ 325 2002 1070 1074
5. S.M. Straus G.S. Bleumink J.P. Dieleman J. van der Lei G.W. ’t Jong J.H. Kingma Antipsychotics and the risk of sudden cardiac death Arch Intern Med 164 2004 1293 1297
6. J.G. Reilly S.A. Ayis I.N. Ferrier S.J. Jones S.H. Thomas QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients Lancet 355 2000 1048 1052
7. J.P. McEvoy J.M. Meyer D.C. Goff H.A. Nasrallah S.M. Davis L. Sullivan Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III Schizophr Res 80 2005 19 32
8. S. Hägg Y. Lindblom T. Mjorndal R. Adolfsson High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia Int Clin Psychopharmacol 21 2006 93 98
9. H.J. Kim H.J. Kim K.E. Lee D.J. Kim S.K. Kim C.W. Ahn Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults Arch Intern Med 164 2004 2169 2175
10. L.A. Adams P. Angulo Recent concepts in non-alcoholic fatty liver disease Diabet Med 22 2005 1129 1133
11. M. Machado H. Cortez-Pinto Non-alcoholic steatohepatitis and metabolic syndrome Curr Opin Clin Nutr Metab Care 9 2006 637 642
12. S.H. Durlacher J.R. Meier R.S. Fisher W.V. Lovitt Jr. Sudden death due to pulmonary fat embolism in chronic alcoholics with fatty livers J Forensic Sci 4 1959 215 228
13. B. Randall Fatty liver and sudden death Hum Pathol 11 1980 147 153
14. M.B. Jones Pulmonary fat emboli associated with acute fatty liver of pregnancy Am J Gastroenterol 88 1993 791 792
15. G. Cheymol Effects of obesity on pharmacokinetics implications for drug therapy Clin Pharmacokinet 39 2000 215 231
16. M. Spatzenegger Y. Horsmans R.K. Verbeeck Differential activities of CYP1A isozymes in hepatic and intestinal microsomes of control and 3-methylcholanthrene-induced rats Pharmacol Toxicol 86 2000 71 77
17. U. Fuhr J. Doehmer N. Battula C. Wolfel I. Flick C. Kudla Biotransformation of methylxanthines in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Allocation of metabolic pathways to isoforms and inhibitory effects of quinolones Toxicology 82 1993 169 189
18. G.M. Su R.M. Sefton M. Murray Down-regulation of rat hepatic microsomal cytochromes P-450 in microvesicular steatosis induced by orotic acid J Pharmacol Exp Ther 291 1999 953 959
19. H. Iber T. Li-Masters Q. Chen S. Yu E.T. Morgan Regulation of hepatic cytochrome P450 2C11 via cAMP: implications for down-regulation in diabetes, fasting, and inflammation J Pharmacol Exp Ther 297 2001 174 180
20. V. Ribeiro M.C. Lechner Cloning and characterization of a novel CYP3A1 allelic variant: analysis of CYP3A1 and CYP3A2 sex-hormone-dependent expression reveals that the CYP3A2 gene is regulated by testosterone Arch Biochem Biophys 293 1992 147 152
21. S. Orrenius Mitochondrial regulation of apoptotic cell death Toxicol Lett 149 2004 19 23
22. H.M. Beere ‘The stress of dying’: the role of heat shock proteins in the regulation of apoptosis J Cell Sci 117 2004 2641 2651
23. H. Inoue A. Tsuji K. Kudo N. Ikeda Pulmonary fat embolism induced by exposure to high ambient temperature in rats with a fatty liver Int J Legal Med 119 2005 275 279
24. M.D. Weltman G.C. Farrell C. Liddle Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation Gastroenterology 111 1996 1645 1653
25. M.D. Weltman G.C. Farrell P. Hall M. Ingelman-Sundberg C. Liddle Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis Hepatology 27 1998 128 133
26. M.T. Donato A. Lahoz N. Jiménez G. Pérez A. Serralta J. Mir Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts Drug Metab Dispos 34 2006 1556 1562
27. W.V. Zhang I. Ramzan M. Murray Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis J Pharmacol Exp Ther 322 2007 770 777
28. P. Honkakoski M. Negishi Regulation of cytochrome P450 (CYP) genes by nuclear receptors Biochem J 347 2000 321 337
29. G. Robertson I. Leclercq G.C. Farrell Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress Am J Physiol Gastrointest Liver Physiol 281 2001 G1135 G1139
30. G.M. Su E. Fiala-Beer J. Weber D. Jahn G.R. Robertson M. Murray Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid Biochem Pharmacol 69 2005 709 717
31. D.J. Waxman Interactions of hepatic cytochromes P-450 with steroid hormones. Regioselectivity and stereospecificity of steroid metabolism and hormonal regulation of rat P-450 enzyme expression Biochem Pharmacol 37 1988 71 84
32. M. Watanabe T. Tateishi M. Asoh H. Nakura M. Tanaka T. Kumai Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats Fundam Clin Pharmacol 13 1999 337 342
33. H. Rittmannsberger U. Meise K. Schauflinger E. Horvath H. Donat H. Hinterhuber Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics Eur Psychiatry 14 1999 33 40
34. J.D. Browning J.D. Horton Molecular mediators of hepatic steatosis and liver injury J Clin Invest 114 2004 147 152
35. B.A. Neuschwander-Tetri S.H. Caldwell Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 37 2003 1202 1219
36. M. Cave I. Deaciuc C. Mendez Z. Song S. Joshi-Barve S. Barve Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition J Nutr Biochem 18 2007 184 195
37. M. Haque A.J. Sanyal The metabolic abnormalities associated with non-alcoholic fatty liver disease Best Pract Res Clin Gastroenterol 16 2002 709 731
38. P.S. Ribeiro H. Cortez-Pinto S. Sola R.E. Castro R.M. Ramalho A. Baptista Hepatocyte apoptosis, expression of death receptors, and activation of NF- κ B in the liver of nonalcoholic and alcoholic steatohepatitis patients Am J Gastroenterol 99 2004 1708 1717
39. A.E. Feldstein A. Canbay P. Angulo M. Taniai L.J. Burgart K.D. Lindor Hepatocyte apoptosis and Fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443
40. A.E. Feldstein A. Canbay M.E. Guicciardi H. Higuchi S.F. Bronk G.J. Gores Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice J Hepatol 39 2003 978 983
41. R.M. Ramalho H. Cortez-Pinto R.E. Castro S. Sola A. Costa M.C. Moura Apoptosis and bcl-2 expression in the livers of patients with steatohepatitis Eur J Gastroenterol Hepatol 18 2006 21 29
42. N. Nieto M. Rojkind Repeated whiskey binges promote liver injury in rats fed a choline-deficient diet J Hepatol 46 2007 330 339
43. Z. Wei D.D. Mousseau Y. Dai X. Cao X.M. Li Haloperidol induces apoptosis via the sigma2 receptor system and Bcl-XS Pharmacogenomics J 6 2006 279 288
44. J. Nordenberg I. Perlmutter G. Lavie E. Beery O. Uziel C. Morgenstern Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines Int J Oncol 27 2005 1097 1103
45. B.J. Vilner W.D. Bowen Modulation of cellular calcium by sigma-2 receptors: release from intracellular stores in human SK-N-SH neuroblastoma cells J Pharmacol Exp Ther 292 2000 900 911
46. W.D. Bowen Sigma receptors: recent advances and new clinical potentials Pharm Acta Helv 74 2000 211 218
47. M. Polydoro N. Schröder M.N. Lima F. Caldana D.C. Laranja E. Bromberg Haloperidol- and clozapine-induced oxidative stress in the rat brain Pharmacol Biochem Behav 78 2004 751 756
48. D. Gebreselassie W.D. Bowen Sigma-2 receptors are specifically localized to lipid rafts in rat liver membranes Eur J Pharmacol 493 2004 19 28
49. H. Rollema M. Skolnik J. D’Engelbronner K. Igarashi E. Usuki N. Castagnoli MPP(+)-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies J Pharmacol Exp Ther 268 1994 380 387
50. S. Imaoka M. Osada Y. Minamiyama T. Yukimura S. Toyokuni S. Takemura Role of phenobarbital-inducible cytochrome P450s as a source of active oxygen species in DNA-oxidation Cancer Lett 203 2004 117 125
51. H.P. Dincsoy D.A. Saelinger Haloperidol-induced chronic cholestatic liver disease Gastroenterology 83 1982 694 700
52. F.J. Ayd Jr. Haloperidol: fifteen years of clinical experience Dis Nerv Syst 33 1972 459 469